Cite
Correction: Real‑world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC‑FFM in ruxolitinib‑refractory acute graft‑versus‑host disease.
MLA
Bonig, Halvard, et al. “Correction: Real‑world Data Suggest Effectiveness of the Allogeneic Mesenchymal Stromal Cells Preparation MSC‑FFM in Ruxolitinib‑refractory Acute Graft‑versus‑host Disease.” Journal of Translational Medicine, vol. 22, no. 1, June 2024, pp. 1–2. EBSCOhost, https://doi.org/10.1186/s12967-024-05348-8.
APA
Bonig, H., Verbeek, M., Herhaus, P., Braitsch, K., Beutel, G., Schmid, C., Müller, N., Bug, G., Döring, M., von Stackelberg, A., Tischer, J., Ayuk, F., Wulf, G., Holtick, U., Pfeffermann, L., Jahrsdörfer, B., Schrezenmeier, H., Kuci, S., Kuci, Z., & Zens, A. (2024). Correction: Real‑world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC‑FFM in ruxolitinib‑refractory acute graft‑versus‑host disease. Journal of Translational Medicine, 22(1), 1–2. https://doi.org/10.1186/s12967-024-05348-8
Chicago
Bonig, Halvard, Mareike Verbeek, Peter Herhaus, Krischan Braitsch, Gernot Beutel, Christoph Schmid, Nadine Müller, et al. 2024. “Correction: Real‑world Data Suggest Effectiveness of the Allogeneic Mesenchymal Stromal Cells Preparation MSC‑FFM in Ruxolitinib‑refractory Acute Graft‑versus‑host Disease.” Journal of Translational Medicine 22 (1): 1–2. doi:10.1186/s12967-024-05348-8.